DIACEUTICS PLC | RNS Reach Story | ||
| Go to market news section | ||
|
Diaceutics PLC
('Diaceutics' or the 'Group')
Belfast investor presentation
Diaceutics PLC (AIM: DXRX), the diagnostic commercialisation company, announces that it will hold a presentation for investors on Monday, 6 April 2020 in Belfast City. The presentation will be given jointly by Diaceutics and Fusion Antibodies plc, the specialists in pre-clinical antibody discovery, engineering and supply for both therapeutic drug and diagnostic applications.
On behalf of Diaceutics, Peter Keeling CEO, and Philip White, CFO, will give a Company update and overview. The event will take place at a venue in central Belfast and will commence with registration at 5.00pm for a 5.15pm start, followed by drinks and networking.
The format of the afternoon will be as follows:
5pm:arrival and registration
5.15pm:Welcome address
5.20pm - 5.50pm:Diaceutics presentation
5.50pm - 6.05pm:Q&A
6.10pm - 6.40pm:Fusion Antibodies presentation
6.40pm - 6.55pm:Q&A
7pm:Canapes, drinks and networking
8pm:Close
If you would like to register to attend, please contact Walbrook PR on 020 7933 8780 or emaildiaceutics@walbrookpr.com.Enquiries:
Diaceutics PLC | www.diaceutics.com | |
Peter Keeling, Chief Executive Officer | Via Walbrook PR | |
Philip White, Chief Financial Officer | ||
Walbrook PR | Tel: +44 (0)20 7933 8780 or diaceutics@walbrookpr.com | |
Anna Dunphy | Mob: +44 (0)7876 741 001 | |
Paul McManus | Mob: +44 (0)7980 541 893 | |
About Diaceutics
Diaceutics PLC is a leading diagnostics data analytics and implementation services provider for global pharmaceutical companies. The Company, quoted on the Alternative Investment Market (AIM) of the London Stock Exchange, is enabling Pharma to accelerate their market penetration and achieve a better return on precision medicine therapies by helping them to revolutionise patient testing. By generating insights from its data lake of clinical laboratory testing data and other data, Diaceutics helps Pharma understand and leverage the diagnostic landscape through initiatives that improve patient testing, leading to better treatment outcomes. The Company works with more than 30 global pharmaceutical companies across hundreds of precision medicine projects. The Company employs a leading global group of experts from the laboratory, diagnostic and pharmaceutical industries. www.diaceutics.com
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
| London Stock Exchange plc is not responsible for and does not check content on this Website. Website users are responsible for checking content. Any news item (including any prospectus) which is addressed solely to the persons and countries specified therein should not be relied upon other than by such persons and/or outside the specified countries. Terms and conditions, including restrictions on use and distribution apply. |
| ©2014London Stock Exchange plc. All rights reserved |
Belfast investor presentation - RNS
Attachments
- Original document
- Permalink
Disclaimer
Diaceutics plc published this content on 17 February 2020 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 17 February 2020 07:06:08 UTC
